Does the media refer more to ACHV or LFCR?

In the previous week, Lifecore Biomedical had 9 more articles in the media than Achieve Life Sciences. MarketBeat recorded 10 mentions for Lifecore Biomedical and 1 mentions for Achieve Life Sciences. Lifecore Biomedical's average media sentiment score of 0.35 beat Achieve Life Sciences' score of 0.00 indicating that Lifecore Biomedical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achieve Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lifecore Biomedical 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LFCR or CTNM?

In the previous week, Lifecore Biomedical had 9 more articles in the media than Contineum Therapeutics. MarketBeat recorded 10 mentions for Lifecore Biomedical and 1 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.61 beat Lifecore Biomedical's score of 0.35 indicating that Contineum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Contineum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ZVRA or LFCR?

In the previous week, Zevra Therapeutics had 20 more articles in the media than Lifecore Biomedical. MarketBeat recorded 30 mentions for Zevra Therapeutics and 10 mentions for Lifecore Biomedical. Zevra Therapeutics' average media sentiment score of 0.41 beat Lifecore Biomedical's score of 0.35 indicating that Zevra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Lifecore Biomedical 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CRMD or LFCR?

In the previous week, Lifecore Biomedical had 8 more articles in the media than CorMedix. MarketBeat recorded 10 mentions for Lifecore Biomedical and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.61 beat Lifecore Biomedical's score of 0.35 indicating that CorMedix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lifecore Biomedical 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer HELP or LFCR?

In the previous week, Lifecore Biomedical had 7 more articles in the media than Cybin. MarketBeat recorded 10 mentions for Lifecore Biomedical and 3 mentions for Cybin. Cybin's average media sentiment score of 0.40 beat Lifecore Biomedical's score of 0.35 indicating that Cybin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lifecore Biomedical 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Lifecore Biomedical (LFCR) Competitors

$4.81 -0.20 (-3.99%)

As of 11:13 AM Eastern

Compare

LFCR vs. ACHV, CTNM, ZVRA, CRMD, and HELP

Should you buy Lifecore Biomedical stock or one of its competitors? MarketBeat compares Lifecore Biomedical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lifecore Biomedical include Achieve Life Sciences (ACHV), Contineum Therapeutics (CTNM), Zevra Therapeutics (ZVRA), CorMedix (CRMD), and Cybin (HELP). These companies are all part of the "pharmaceuticals" industry.

How does Lifecore Biomedical compare to Achieve Life Sciences?

Achieve Life Sciences (NASDAQ:ACHV) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 1.8% of Achieve Life Sciences shares are held by insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Lifecore Biomedical has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A
Lifecore Biomedical	$128.87M	1.41	-$40.50M	-$1.07	N/A

In the previous week, Lifecore Biomedical had 9 more articles in the media than Achieve Life Sciences. MarketBeat recorded 10 mentions for Lifecore Biomedical and 1 mentions for Achieve Life Sciences. Lifecore Biomedical's average media sentiment score of 0.35 beat Achieve Life Sciences' score of 0.00 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lifecore Biomedical	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Achieve Life Sciences has a beta of 2.24, meaning that its share price is 124% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Achieve Life Sciences has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-193.49%	-111.88%
Lifecore Biomedical	-29.93%	N/A	-16.16%

Achieve Life Sciences presently has a consensus target price of $16.00, suggesting a potential upside of 137.14%. Lifecore Biomedical has a consensus target price of $6.50, suggesting a potential upside of 35.14%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Achieve Life Sciences is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Lifecore Biomedical beats Achieve Life Sciences on 10 of the 16 factors compared between the two stocks.

How does Lifecore Biomedical compare to Contineum Therapeutics?

Lifecore Biomedical (NASDAQ:LFCR) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

Lifecore Biomedical has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

In the previous week, Lifecore Biomedical had 9 more articles in the media than Contineum Therapeutics. MarketBeat recorded 10 mentions for Lifecore Biomedical and 1 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.61 beat Lifecore Biomedical's score of 0.35 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Contineum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lifecore Biomedical has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.41	-$40.50M	-$1.07	N/A
Contineum Therapeutics	$50M	11.09	-$59.98M	-$1.73	N/A

Contineum Therapeutics has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Contineum Therapeutics	N/A	-24.73%	-23.51%

Lifecore Biomedical presently has a consensus target price of $6.50, indicating a potential upside of 35.14%. Contineum Therapeutics has a consensus target price of $20.25, indicating a potential upside of 37.38%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Contineum Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

83.4% of Lifecore Biomedical shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by insiders. Comparatively, 7.9% of Contineum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Lifecore Biomedical beats Contineum Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Lifecore Biomedical compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

In the previous week, Zevra Therapeutics had 20 more articles in the media than Lifecore Biomedical. MarketBeat recorded 30 mentions for Zevra Therapeutics and 10 mentions for Lifecore Biomedical. Zevra Therapeutics' average media sentiment score of 0.41 beat Lifecore Biomedical's score of 0.35 indicating that Zevra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lifecore Biomedical	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 3.7% of Zevra Therapeutics shares are held by insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Zevra Therapeutics presently has a consensus price target of $27.14, suggesting a potential upside of 139.99%. Lifecore Biomedical has a consensus price target of $6.50, suggesting a potential upside of 35.14%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Zevra Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Zevra Therapeutics has a net margin of 42.82% compared to Lifecore Biomedical's net margin of -29.93%. Zevra Therapeutics' return on equity of 54.54% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	42.82%	54.54%	34.15%
Lifecore Biomedical	-29.93%	N/A	-16.16%

Zevra Therapeutics has higher earnings, but lower revenue than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	6.31	$83.23M	$0.92	12.29
Lifecore Biomedical	$128.87M	1.41	-$40.50M	-$1.07	N/A

Zevra Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Summary

Zevra Therapeutics beats Lifecore Biomedical on 12 of the 16 factors compared between the two stocks.

How does Lifecore Biomedical compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

CorMedix has a net margin of 45.25% compared to Lifecore Biomedical's net margin of -29.93%. CorMedix's return on equity of 45.57% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Lifecore Biomedical	-29.93%	N/A	-16.16%

CorMedix has higher revenue and earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$400.05M	1.45	$163.05M	$2.13	3.47
Lifecore Biomedical	$128.87M	1.41	-$40.50M	-$1.07	N/A

CorMedix has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

In the previous week, Lifecore Biomedical had 8 more articles in the media than CorMedix. MarketBeat recorded 10 mentions for Lifecore Biomedical and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.61 beat Lifecore Biomedical's score of 0.35 indicating that CorMedix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lifecore Biomedical	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CorMedix currently has a consensus price target of $14.86, indicating a potential upside of 100.91%. Lifecore Biomedical has a consensus price target of $6.50, indicating a potential upside of 35.14%. Given CorMedix's stronger consensus rating and higher probable upside, research analysts plainly believe CorMedix is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

34.2% of CorMedix shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 3.5% of CorMedix shares are held by insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

CorMedix beats Lifecore Biomedical on 13 of the 16 factors compared between the two stocks.

How does Lifecore Biomedical compare to Cybin?

Cybin (NASDAQ:HELP) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Cybin presently has a consensus target price of $45.25, suggesting a potential upside of 342.67%. Lifecore Biomedical has a consensus target price of $6.50, suggesting a potential upside of 35.14%. Given Cybin's stronger consensus rating and higher possible upside, research analysts clearly believe Cybin is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cybin has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-68.27%	-58.26%
Lifecore Biomedical	-29.93%	N/A	-16.16%

Cybin has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

In the previous week, Lifecore Biomedical had 7 more articles in the media than Cybin. MarketBeat recorded 10 mentions for Lifecore Biomedical and 3 mentions for Cybin. Cybin's average media sentiment score of 0.40 beat Lifecore Biomedical's score of 0.35 indicating that Cybin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lifecore Biomedical	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

17.9% of Cybin shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 15.0% of Cybin shares are owned by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lifecore Biomedical has higher revenue and earnings than Cybin. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$148M	-$4.23	N/A
Lifecore Biomedical	$128.87M	1.41	-$40.50M	-$1.07	N/A

Summary

Lifecore Biomedical beats Cybin on 9 of the 15 factors compared between the two stocks.

Get Lifecore Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFCR vs. The Competition

Export

Metric	Lifecore Biomedical	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$183.21M	$11.88B	$7.03B	$12.96B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-4.52	788.46	269.91	24.87
Price / Sales	1.41	969.81	654.69	108.21
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	11.45	10.37	11.40	6.45
Net Income	-$40.50M	$2.77B	$3.45B	$347.50M
7 Day Performance	9.57%	2.26%	3.66%	3.77%
1 Month Performance	1.26%	-1.28%	-0.49%	-0.40%
1 Year Performance	-33.56%	191.26%	77.51%	23.55%

Lifecore Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFCR Lifecore Biomedical	1.7456 of 5 stars	$4.81 -4.0%	$6.50 +35.1%	-30.8%	$183.21M	$128.87M	N/A	690	Earnings Report
ACHV Achieve Life Sciences	2.0682 of 5 stars	$6.47 +2.4%	$16.00 +147.3%	+166.0%	$648.80M	N/A	N/A	20
CTNM Contineum Therapeutics	1.6179 of 5 stars	$15.90 -0.2%	$20.25 +27.4%	+132.5%	$595.57M	$50M	N/A	31	Positive News
ZVRA Zevra Therapeutics	4.3292 of 5 stars	$10.52 +4.6%	$26.86 +155.3%	-3.8%	$594.40M	$106.47M	5.29	20	News Coverage Earnings Report Analyst Forecast Analyst Revision
CRMD CorMedix	2.5529 of 5 stars	$7.52 -0.4%	$14.86 +97.6%	-28.0%	$592.31M	$311.71M	3.53	30	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFCR) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lifecore Biomedical (LFCR) Competitors

LFCR vs. ACHV, CTNM, ZVRA, CRMD, and HELP

How does Lifecore Biomedical compare to Achieve Life Sciences?

Summary

How does Lifecore Biomedical compare to Contineum Therapeutics?

Summary

How does Lifecore Biomedical compare to Zevra Therapeutics?

Summary

How does Lifecore Biomedical compare to CorMedix?

Summary

How does Lifecore Biomedical compare to Cybin?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR vs. The Competition

Lifecore Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lifecore Biomedical (LFCR) Competitors

LFCR vs. ACHV, CTNM, ZVRA, CRMD, and HELP

How does Lifecore Biomedical compare to Achieve Life Sciences?

Do institutionals and insiders hold more shares of ACHV or LFCR?

Which has stronger valuation & earnings, ACHV or LFCR?

Does the media refer more to ACHV or LFCR?

Which has more risk & volatility, ACHV or LFCR?

Is ACHV or LFCR more profitable?

Do analysts rate ACHV or LFCR?

Summary

How does Lifecore Biomedical compare to Contineum Therapeutics?

Which has more risk and volatility, LFCR or CTNM?

Does the media prefer LFCR or CTNM?

Which has stronger valuation & earnings, LFCR or CTNM?

Is LFCR or CTNM more profitable?

Do analysts recommend LFCR or CTNM?

Do institutionals & insiders have more ownership in LFCR or CTNM?

Summary

How does Lifecore Biomedical compare to Zevra Therapeutics?

Does the media refer more to ZVRA or LFCR?

Do institutionals & insiders have more ownership in ZVRA or LFCR?

Do analysts rate ZVRA or LFCR?

Is ZVRA or LFCR more profitable?

Which has stronger valuation and earnings, ZVRA or LFCR?

Which has more risk & volatility, ZVRA or LFCR?

Summary

How does Lifecore Biomedical compare to CorMedix?

Is CRMD or LFCR more profitable?

Which has preferable earnings & valuation, CRMD or LFCR?

Which has more volatility & risk, CRMD or LFCR?

Does the media favor CRMD or LFCR?

Do analysts recommend CRMD or LFCR?

Do insiders and institutionals believe in CRMD or LFCR?

Summary

How does Lifecore Biomedical compare to Cybin?

Do analysts rate HELP or LFCR?

Is HELP or LFCR more profitable?

Which has more volatility & risk, HELP or LFCR?

Does the media prefer HELP or LFCR?

Do insiders & institutionals hold more shares of HELP or LFCR?

Which has stronger valuation & earnings, HELP or LFCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR vs. The Competition

Lifecore Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools